High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$26.0M
$26,005,146
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Ragosa Mark
• CFO
10b5-1 SellΔOwn -60.8%
2026-03-09
$866,584
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
10b5-1 SellΔOwn -60.8%
|
2026-03-09 | $866,584 | S | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
Other
|
2026-03-09 | $46,604 | M | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
Other
|
2026-03-09 | $186,711 | M | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
Other
|
2026-03-09 | $249,463 | M | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
Other
|
2026-03-09 | $277,026 | M | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Ragosa Mark
• CFO
10b5-1 SellΔOwn -36.8%
2026-03-09
$819,574
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
10b5-1 SellΔOwn -36.8%
|
2026-03-09 | $819,574 | S | Form 4 |
|
KNSA
M
Kiniksa Pharmaceuticals International, plc
Paolini John F.
• Officer • CHIEF MEDICAL OFFICER
Other
2026-03-02
$414,400
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Officer • CHIEF MEDICAL OFFICER
Other
|
2026-03-02 | $414,400 | M | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Paolini John F.
• Officer • CHIEF MEDICAL OFFICER
10b5-1 Sell
2026-03-02
$262,387
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Officer • CHIEF MEDICAL OFFICER
10b5-1 Sell
|
2026-03-02 | $262,387 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Paolini John F.
• Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -24.9%
2026-03-02
$997,368
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -24.9%
|
2026-03-02 | $997,368 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Paolini John F.
• Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -11.9%
2026-03-02
$533,185
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -11.9%
|
2026-03-02 | $533,185 | S | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
Other
|
2026-02-12 | $41,614 | M | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Quart Barry D
• Director
10b5-1 SellΔOwn -17.7%
2026-02-12
$121,050
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
10b5-1 SellΔOwn -17.7%
|
2026-02-12 | $121,050 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Quart Barry D
• Director
10b5-1 Sell
2026-02-10
$4,950
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
10b5-1 Sell
|
2026-02-10 | $4,950 | S | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
Other
|
2026-02-10 | $1,702 | M | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Ragosa Mark
• CFO
10b5-1 SellΔOwn -41.9%
2026-02-09
$381,719
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
10b5-1 SellΔOwn -41.9%
|
2026-02-09 | $381,719 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Ragosa Mark
• CFO
10b5-1 SellΔOwn -30.4%
2026-02-09
$390,535
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
10b5-1 SellΔOwn -30.4%
|
2026-02-09 | $390,535 | S | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
Other
|
2026-02-09 | $41,760 | M | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
Other
|
2026-02-09 | $108,611 | M | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
Other
|
2026-02-04 | $40,253 | M | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Quart Barry D
• Director
10b5-1 SellΔOwn -17.2%
2026-02-04
$117,142
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
10b5-1 SellΔOwn -17.2%
|
2026-02-04 | $117,142 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Quart Barry D
• Director
10b5-1 SellΔOwn -50.0%
2026-02-03
$567,143
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
10b5-1 SellΔOwn -50.0%
|
2026-02-03 | $567,143 | S | Form 4 |
|
KNSA
M
Kiniksa Pharmaceuticals International, plc
Quart Barry D
• Director
Other
2026-02-03
$193,808
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
Other
|
2026-02-03 | $193,808 | M | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
Other
|
2026-02-02 | $12,840 | M | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Quart Barry D
• Director
10b5-1 Sell
2026-02-02
$37,350
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
10b5-1 Sell
|
2026-02-02 | $37,350 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Ragosa Mark
• CFO
10b5-1 SellΔOwn -38.6%
2026-01-08
$502,680
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
10b5-1 SellΔOwn -38.6%
|
2026-01-08 | $502,680 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Tessari Eben
• COO
10b5-1 SellΔOwn -42.0%
2025-12-15
$500,715
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
10b5-1 SellΔOwn -42.0%
|
2025-12-15 | $500,715 | S | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
Other
|
2025-12-15 | $52,980 | M | Form 4 |
|
KNSA
M
Kiniksa Pharmaceuticals International, plc
Quart Barry D
• Director
Equity Compensation
2025-12-15
$0
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
Equity Compensation
|
2025-12-15 | $0 | M | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Quart Barry D
• Director
10b5-1 SellΔOwn -61.6%
2025-12-15
$835,555
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
10b5-1 SellΔOwn -61.6%
|
2025-12-15 | $835,555 | S | Form 4 |
|
KNSA
M
Kiniksa Pharmaceuticals International, plc
Quart Barry D
• Director
Other
2025-12-15
$208,536
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
Other
|
2025-12-15 | $208,536 | M | Form 4 |
|
KNSA
M
Kiniksa Pharmaceuticals International, plc
Tessari Eben
• COO
Equity Compensation
2025-12-15
$0
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
Equity Compensation
|
2025-12-15 | $0 | M | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
10b5-1 Sell
|
2025-11-26 | $8,578 | S | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
Other
|
2025-11-26 | $4,578 | M | Form 4 |
|
KNSA
M
Kiniksa Pharmaceuticals International, plc
Tessari Eben
• COO
Equity Compensation
2025-11-26
$0
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
Equity Compensation
|
2025-11-26 | $0 | M | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
10b5-1 Sell
|
2025-11-17 | $25,852 | S | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
Other
|
2025-11-17 | $57,395 | M | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Tessari Eben
• COO
10b5-1 SellΔOwn -34.2%
2025-11-17
$488,372
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
10b5-1 SellΔOwn -34.2%
|
2025-11-17 | $488,372 | S | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
Other
|
2025-11-12 | $615,507 | M | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Ragosa Mark
• CFO
10b5-1 SellΔOwn -39.0%
2025-11-12
$814,706
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
10b5-1 SellΔOwn -39.0%
|
2025-11-12 | $814,706 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Paolini John F.
• Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -57.4%
2025-10-31
$3,065,610Large
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -57.4%
|
2025-10-31 | $3,065,610Large | S | Form 4 |
|
KNSA
M
Kiniksa Pharmaceuticals International, plc
Paolini John F.
• Officer • CHIEF MEDICAL OFFICER
Other
2025-10-31
$406,180
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Officer • CHIEF MEDICAL OFFICER
Other
|
2025-10-31 | $406,180 | M | Form 4 |
|
KNSA
M
Kiniksa Pharmaceuticals International, plc
Paolini John F.
• Officer • CHIEF MEDICAL OFFICER
Other
2025-10-31
$138,860
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Officer • CHIEF MEDICAL OFFICER
Other
|
2025-10-31 | $138,860 | M | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
Other
|
2025-10-28 | $3,093 | M | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
10b5-1 Sell
|
2025-10-28 | $4,100 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Patel Sanj K
• CEO
10b5-1 SellΔOwn -46.6%
2025-10-22
$3,781,654Large
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CEO
10b5-1 SellΔOwn -46.6%
|
2025-10-22 | $3,781,654Large | S | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CEO
Other
|
2025-10-22 | $370,082 | M | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CEO
Other
|
2025-10-21 | $149,458 | M | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Patel Sanj K
• CEO
10b5-1 SellΔOwn -26.0%
2025-10-21
$1,524,863Large
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CEO
10b5-1 SellΔOwn -26.0%
|
2025-10-21 | $1,524,863Large | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Megna Michael R
• Officer • CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -32.9%
2025-10-20
$520,268
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Officer • CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -32.9%
|
2025-10-20 | $520,268 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Megna Michael R
• Officer • CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -48.0%
2025-10-20
$1,442,514Large
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Officer • CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -48.0%
|
2025-10-20 | $1,442,514Large | S | Form 4 |
|
KNSA
M
Kiniksa Pharmaceuticals International, plc
Megna Michael R
• Officer • CHIEF ACCOUNTING OFFICER
Other
2025-10-20
$137,588
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Officer • CHIEF ACCOUNTING OFFICER
Other
|
2025-10-20 | $137,588 | M | Form 4 |
|
KNSA
M
Kiniksa Pharmaceuticals International, plc
Megna Michael R
• Officer • CHIEF ACCOUNTING OFFICER
Other
2025-10-20
$117,677
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Officer • CHIEF ACCOUNTING OFFICER
Other
|
2025-10-20 | $117,677 | M | Form 4 |
|
KNSA
M
Kiniksa Pharmaceuticals International, plc
Megna Michael R
• Officer • CHIEF ACCOUNTING OFFICER
Other
2025-10-20
$109,124
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Officer • CHIEF ACCOUNTING OFFICER
Other
|
2025-10-20 | $109,124 | M | Form 4 |
|
KNSA
M
Kiniksa Pharmaceuticals International, plc
Megna Michael R
• Officer • CHIEF ACCOUNTING OFFICER
Other
2025-10-20
$80,349
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Officer • CHIEF ACCOUNTING OFFICER
Other
|
2025-10-20 | $80,349 | M | Form 4 |
|
KNSA
M
Kiniksa Pharmaceuticals International, plc
Megna Michael R
• Officer • CHIEF ACCOUNTING OFFICER
Other
2025-10-20
$12,260
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Officer • CHIEF ACCOUNTING OFFICER
Other
|
2025-10-20 | $12,260 | M | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Patel Sanj K
• CEO
10b5-1 SellΔOwn -16.6%
2025-10-20
$877,386
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CEO
10b5-1 SellΔOwn -16.6%
|
2025-10-20 | $877,386 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Patel Sanj K
• CEO
10b5-1 SellΔOwn -42.5%
2025-10-20
$3,839,629Large
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CEO
10b5-1 SellΔOwn -42.5%
|
2025-10-20 | $3,839,629Large | S | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CEO
Other
|
2025-10-20 | $460,742 | M | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Tessari Eben
• COO
10b5-1 SellΔOwn -28.8%
2025-10-14
$444,835
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
10b5-1 SellΔOwn -28.8%
|
2025-10-14 | $444,835 | S | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
Other
|
2025-10-14 | $57,395 | M | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
10b5-1 Sell
|
2025-10-14 | $21,008 | S | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
Other
|
2025-09-29 | $752,640 | M | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Tessari Eben
• COO
10b5-1 SellΔOwn -54.9%
2025-09-29
$1,609,860Large
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
10b5-1 SellΔOwn -54.9%
|
2025-09-29 | $1,609,860Large | S | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
Other
|
2025-09-15 | $57,395 | M | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
10b5-1 Sell
|
2025-09-15 | $13,172 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Tessari Eben
• COO
10b5-1 SellΔOwn -31.5%
2025-09-15
$584,804
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
10b5-1 SellΔOwn -31.5%
|
2025-09-15 | $584,804 | S | Form 4 |